Mendus | BiotechTV

top of page

Pareto Securities Healthcare Conference: Mendus' cellular immunotherapy has been making progress in numerous cancers - being thoughtful about the setting and goal of treatment have been keys

CEO Erik Manting describes vididencel and the progress the company has been making in AML, CML, and ovarian cancer. Additional CML data is expected in this second half of the year.

Company News

4 hours ago

BIO-Europe: Mendus is developing cancer immunotherapies that focus on dendritic cell biology - an AML program will have a data update at #ASH24

CEO Erik Manting describes the rationale for focusing on dendritic cell biology, and covers previous data the company has presented in...

Company News

Nov 5, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page

Pareto Securities Healthcare Conference: Mendus' cellular immunotherapy has been making progress in numerous cancers - being thoughtful about the setting and goal of treatment have been keys

BIO-Europe: Mendus is developing cancer immunotherapies that focus on dendritic cell biology - an AML program will have a data update at #ASH24

Follow BiotechTV

Sponsors

Sponsor Spotlight